ELV icon

Elevance Health

311.46 USD
-2.54
0.81%
Updated Aug 26, 3:30 PM EDT
1 day
-0.81%
5 days
-0.37%
1 month
8.91%
3 months
-17.16%
6 months
-19.34%
Year to date
-14.86%
1 year
-42.81%
5 years
15.27%
10 years
119.09%
 

About: Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of June 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.

Employees: 104,200

0
Funds holding %
of 7,433 funds
0
Analysts bullish %
of 10 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

69% more call options, than puts

Call options by funds: $612M | Put options by funds: $363M

1.08% more ownership

Funds ownership: 88.1% [Q1] → 89.18% (+1.08%) [Q2]

1% less repeat investments, than reductions

Existing positions increased: 586 | Existing positions reduced: 591

5% less funds holding

Funds holding: 1,633 [Q1] → 1,551 (-82) [Q2]

10% less capital invested

Capital invested by funds: $87B [Q1] → $78.2B (-$8.79B) [Q2]

20% less first-time investments, than exits

New positions opened: 143 | Existing positions closed: 178

26% less funds holding in top 10

Funds holding in top 10: 43 [Q1] → 32 (-11) [Q2]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$297
5%
downside
Avg. target
$368
18%
upside
High target
$478
53%
upside

10 analyst ratings

positive
80%
neutral
20%
negative
0%
Wells Fargo
Stephen Baxter
6%upside
$330
Overweight
Maintained
15 Aug 2025
Baird
Michael Ha
5%downside
$297
Neutral
Maintained
25 Jul 2025
JP Morgan
Lisa Gill
23%upside
$384
Overweight
Maintained
22 Jul 2025
Barclays
Andrew Mok
5%upside
$327
Overweight
Maintained
22 Jul 2025
UBS
A.J. Rice
40%upside
$435
Buy
Maintained
18 Jul 2025

Financial journalist opinion

Based on 13 articles about ELV published over the past 30 days

Neutral
Zacks Investment Research
4 days ago
Can Elevance Health's Value-Based Care Strategy Fuel Long-Term Growth?
ELV's focus on value-based care, Carelon integration and CareBridge acquisition drives membership and revenue growth.
Can Elevance Health's Value-Based Care Strategy Fuel Long-Term Growth?
Neutral
Seeking Alpha
4 days ago
Elevance Health - Piggy Bank Or Headache?
Elevance and peers face earnings pressure from rising medical costs, driven by deferred care, expensive drugs, and persistent medical inflation. The segment has re-rated, and now offers good value. Investor sentiment has returned, and capital is rotating into healthcare.
Elevance Health - Piggy Bank Or Headache?
Neutral
Zacks Investment Research
5 days ago
UNH or ELV: Which Healthcare Titan Will Regain Investor Trust First?
UnitedHealth and Elevance battle rising costs, but scale, Optum, and Buffett's backing give UNH the edge in restoring investor trust.
UNH or ELV: Which Healthcare Titan Will Regain Investor Trust First?
Positive
Zacks Investment Research
5 days ago
Elevance Shoots for the Stars But Lands at 3.5: $375M Bonus Gone?
Federal judge dismisses ELV's lawsuit challenging Medicare Advantage star ratings, leading to a $375M bonus loss tied to its star score.
Elevance Shoots for the Stars But Lands at 3.5: $375M Bonus Gone?
Negative
Reuters
1 week ago
Elevance Health loses bid to challenge US Medicare star ratings
A federal judge in Texas on Tuesday rejected Elevance Health's challenge of the U.S. government's calculation for the health insurer's star ratings for some of its government-backed Medicare plans after the company said improper rounding cost it at least $375 million.
Elevance Health loses bid to challenge US Medicare star ratings
Neutral
Zacks Investment Research
1 week ago
Food as Medicine: Elevance Health & NACHC Integrate Nutrition in Care
ELV partners with NACHC to bring Food as Medicine into primary care, targeting nutritional insecurities and chronic disease.
Food as Medicine: Elevance Health & NACHC Integrate Nutrition in Care
Neutral
Business Wire
1 week ago
Elevance Health and National Association of Community Health Centers Partnership Integrates Food as Medicine With Primary Care
INDIANAPOLIS--(BUSINESS WIRE)-- #ElevanceHealth--Elevance Health and the National Association of Community Health Centers (NACHC) are proud to announce the integration of Food as Medicine (FAM) programming with primary care Community Health Centers (CHCs). This milestone - built on a shared commitment to whole health and community-centered innovation - marks a transformative step forward in addressing food/nutrition insecurity and diet-related chronic conditions through clinical integration. A Whole Health Appro.
Elevance Health and National Association of Community Health Centers Partnership Integrates Food as Medicine With Primary Care
Positive
Zacks Investment Research
1 week ago
When 90% Isn't an A+: Elevance's Cost Crunch and Carelon's Cushion
ELV trims 2025 outlook as medical costs climb, but commercial growth and Carelon's momentum aim to steady performance.
When 90% Isn't an A+: Elevance's Cost Crunch and Carelon's Cushion
Negative
Zacks Investment Research
2 weeks ago
When a Healthcare Giant Gets Sick: Elevance Health's 20% YTD Decline
ELV's 20% YTD slump reflects shrinking memberships, rising costs and deepening analyst pessimism despite long-term growth levers.
When a Healthcare Giant Gets Sick: Elevance Health's 20% YTD Decline
Positive
24/7 Wall Street
2 weeks ago
3 Stocks That Could Double Before 2027
These stocks have high upside potential through 2027. They're sitting at solid discounts and have good fundamentals.
3 Stocks That Could Double Before 2027
Charts implemented using Lightweight Charts™